| Aug 15 |
TFF Pharmaceuticals GAAP EPS of -$1.22 misses by $0.41, revenue of $0.65M beats by $0.5M
|
| Aug 14 |
TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 14 |
TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
|
| Aug 6 |
TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
|
| Jun 24 |
TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection
|
| Jun 19 |
3 52-Week-Low Losers Ready to Become Big-Time Stock Winners
|
| May 23 |
TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
|
| May 20 |
TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing
|
| May 20 |
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
|
